Zhang DP, et al. - Via performing a network meta-analysis, researchers compared the efficacy of sodium glucose cotransporter type 2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, metformin, sulfonylurea and thiazolidinediones in improving left ventricular (LV) remodeling in patients with type 2 diabetes and/or cardiovascular disease. Searching four electronic databases (PubMed, EMBASE, Cochrane Library and Web of Science), they included 48 studies (36 RCTs and 12 cohort studies), comprising a total sample size of 4,790 individuals. The analysis revealed a more significant association of GLP-1 agonists with improved left ventricular ejection fraction, LV end-systolic volume and mitral inflow E velocity to tissue Doppler e′ ratio, a more meaningful association of SGLT-2 inhibitors with improved LV end-diastolic diameter and E/e′ and a more robust association of DPP-4 inhibitors with a negative impact on LV end-diastolic volume when compared with placebos. Pairwise comparisons suggest SGLT-2 inhibitors as superior to other drugs. Thus, for treating hyperglycemia and reducing cardiovascular comorbidities, novel therapeutic options are GLP-1 agonist and SGLT-2 inhibitorz.